---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic burden and healthcare resource utilization. Topics: Treatment use among 1332 patients with genetically confirmed AMKD in the United States: conference poster report; Medicare expenditures for people with kidney failure; Medicare fee-for-service expenditures for people with CKD; Per person per year Medicare fee-for-service spending among older adults with CKD, by race and CKD stage; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### AMKD-specific health care resource utilization and cost studies

No evidence found.

<a id="topic-2.2.1.8.2-2"></a>

### Treatment use among 1332 patients with genetically confirmed AMKD in the United States: conference poster report

> “Patients with evidence of diabetes, autosomal dominant polycystic kidney disease, or IgA nephropathy were excluded, leaving 1332 patients with a mean (SD) age of 45.6 (15.4) years.”
> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”
> “Within the study period, 35.7% of patients had at least 1 administration or fill of a RAAS inhibitor, 35% of a calcium channel blocker, 27.9% of a beta blocker, 10.5% of an SGLT2 inhibitor, and 4.4% of a GLP-1 receptor agonist.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="topic-2.2.1.8.2-3"></a>

### Medicare expenditures for people with kidney failure

> “Total Medicare costs for people with ESRD increased to an all-time high of $55.3 billion in 2023”
> “MA costs for people with ESRD ($27.7 billion) exceeded FFS costs ($24.4 billion) for the first time in 2023”
> “In 2023, PPPY costs for people with FFS Medicare coverage with ESRD who were not eligible for Medicaid were $68,202; costs for people with FFS who were dual-eligible for Medicaid were 49% higher, at $101,730.”
> “Inflation-adjusted PPPY costs for people with FFS coverage receiving in-center HD in 2023 were $15,377 higher than costs for beneficiaries on PD.”

Source: [USRDS Annual Data Report, ESRD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd)

<a id="topic-2.2.1.8.2-4"></a>

### Medicare fee-for-service expenditures for people with CKD

> “The yearly cost per person with FFS coverage with CKD was $31,176 in 2023, which is about 15% less than it was in 2013”
> “Total costs for people who already had CKD increased over the last decade, reaching $104.3 billion in 2023.”
> “Inflation-adjusted PPPY costs for adults with Medicare FFS coverage with CKD as of January 1 of each year were consistently highest for those with stage 4-5 CKD, intermediate for those with stage 3 CKD, and lowest for those with stages 1-2 CKD.”

Source: [USRDS Annual Data Report, CKD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd)

<a id="topic-2.2.1.8.2-5"></a>

### Per person per year Medicare fee-for-service spending among older adults with CKD, by race and CKD stage

| Older adults with CKD, 2023 | All CKD | Stages 1-2 | Stage 3 | Stages 4-5 |
| --- | --- | --- | --- | --- |
| All | “$30,141” | “$26,241” | “$29,176” | “$42,172” |
| White | “$29,525” | “$25,874” | “$28,696” | “$40,577” |
| Black | “$35,178” | “$27,820” | “$33,408” | “$49,197” |

Source: [USRDS Annual Data Report, CKD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd)

<a id="topic-2.2.1.8.2-6"></a>

### Health care resource utilization and costs in 844 patients with FSGS and matched controls

> “Patients with FSGS (n = 844; first claim = index event) between April 2016 and December 2018 were matched on index date, age, sex, and race to non-FSGS controls (n = 1688).”
> “Mean total medical costs were higher in FSGS ($59,753 vs. $8431 PPPY; P < 0.0001), driven by outpatient costs. Nephrotic range proteinuria was associated with higher all-cause inpatient, outpatient, and prescription costs versus nonnephrotic patients (all P < 0.0001), resulting in higher total costs ($70,481 vs. $36,099 PPPY; P < 0.0001).”

Source: [Kalantar-Zadeh et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8484118/)

<a id="topic-2.2.1.8.2-7"></a>

### Health care resource utilization and costs in FSGS by proteinuria and CKD stage: 9899 patients in a US claims and EHR database

> “In this descriptive, noninterventional, retrospective cohort study, 9899 patients were identified between January 2016 and December 2020 in Optum de-identified Market Clarity Data”
> “There was a consistent trend toward higher health care resource utilization and total costs with both chronic kidney disease progression (stage 1-5/kidney failure) and higher levels of proteinuria”
> “The observed prevalence of FSGS increased in the US and was highest among Black individuals. More advanced chronic kidney disease and higher levels of proteinuria were both associated with greater health care resource utilization and costs.”

Source: [Bensink et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41222995/)

<a id="topic-2.2.1.8.2-8"></a>

### Health care resource utilization and costs in FSGS-attributed kidney failure

> “The FSGS cohort and Medicare Coverage and 1-year Medicare Coverage subgroups included 25,699, 6,340, and 5,575 patients, respectively.”
> “In the Medicare Coverage and 1-year Medicare Coverage subgroups, 76.6% and 74.2% required inpatient admission, 69.9% and 67.3% visited the emergency room, and mean monthly health care costs were $6,752 and $5,575 in the year postindex, respectively.”
> “Drug costs may be underestimated because Medicare Part D coverage was not required; kidney acquisition costs were not available.”

Source: [Bensink et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10831785/)

<a id="topic-2.2.1.8.2-9"></a>

### Health care resource utilization and costs in 2515 US veterans with FSGS

> “The study included 2,515 veterans with FSGS who were followed for an average of 8.9 years.”
> “Overall, 43.3% underwent dialysis and 5.8% had a kidney transplant.”
> “During the first year post-index, 40% had an inpatient admission and 33% visited the emergency room; mean total healthcare cost per patient in the analysis was $36,543.”

Source: [Goldschmidt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11642916/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
